These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 36771465)

  • 41. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
    Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
    Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
    Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
    Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
    Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.
    Yacoub H; Ben Azouz S; Hassine H; Debbabi H; Cherif D; Ghayeb F; Boukriba S; Kchir H; Maamouri N
    J Med Case Rep; 2023 Apr; 17(1):169. PubMed ID: 37106413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Autoimmune mediated cholestatic liver diseases].
    Mayer LS; Käser R; Böttler T
    Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of primary sclerosing cholangitis.
    Floreani A; De Martin S
    Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel.
    Alvaro D; Carpino G; Craxi A; Floreani A; Moschetta A; Invernizzi P
    Liver Int; 2020 Nov; 40(11):2590-2601. PubMed ID: 32757367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis.
    Martinez-Gili L; Pechlivanis A; McDonald JAK; Begum S; Badrock J; Dyson JK; Jones R; Hirschfield G; Ryder SD; Sandford R; Rushbrook S; Thorburn D; Taylor-Robinson SD; Crossey MME; Marchesi JR; Mells G; Holmes E; Jones D
    Gut Microbes; 2023; 15(1):2208501. PubMed ID: 37191344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
    Chen W; Wei Y; Xiong A; Li Y; Guan H; Wang Q; Miao Q; Bian Z; Xiao X; Lian M; Zhang J; Li B; Cao Q; Fan Z; Zhang W; Qiu D; Fang J; Gershwin ME; Yang L; Tang R; Ma X
    Clin Rev Allergy Immunol; 2020 Feb; 58(1):25-38. PubMed ID: 30900136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.
    Abenavoli L; Procopio AC; Fagoonee S; Pellicano R; Carbone M; Luzza F; Invernizzi P
    Diseases; 2020 Jun; 8(2):. PubMed ID: 32532037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Mayo MJ
    Hepatology; 2022 Aug; 76(2):518-531. PubMed ID: 35152430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.